The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Treating severe depression with VNS

    The vagus nerve stimulator (VNS), “would have been unimaginable only a generation ago. After being implanted in a patient’s chest, … research suggests that repeated electronic stimulation of the vagus nerve can help treat severe depression”, says The New York Times.

    It’s an interesting article, but here’s what you need know.

    The VNS system is not first-line treatment. It’s added to other treatments of recurrent severe depression.

    • What it is: a nerve stimulator, surgically implanted in the chest (like a pacemaker)
    • When it’s used: for recurrent severe depression in adults who do not respond to other treatments
    • Experience: Used to treat epilepsy since 1997
    • Patient control: Hold a magnet over the device to turn it off

    There are risks associated with its placement.

    • Surgical complications
    • Vagus nerve damage
    • Skin irritation
    • Pain at the placement site
    • Infection
    • Movement after placement and disconnection of the wires

    Side effects during the first 3 months that occur in more than 10% of people treated:

    • Voice alteration 58%
    • Cough 24%
    • Neck pain 16%
    • Difficulty breathing 14%
    • Difficulty swallowing 13%
    • Itching 11%

    The side effects are not trivial, but neither is the disease being treated.

    Clinical trial results show VNS is not a panacea.

    • At 3 months after starting treatment: no effect
    • At 1 year: 56% of patients who could be evaluated reported “meaningful” benefit
    • At 2 years: 57% of patients who were available to evaluate had “meaningful” benefit
    • Overall at 2 years: 38% of all patients who started the study had “meaningful” benefit
    • Some people actually got worse

    More information is here and here. And a detailed review of the clinical trial history of VNS is here.

    Right now, VNS is the best treatment available for a difficult-to-treat situation.

    9/10/06 9:19 JR

    Leave a Comment

    You must be logged in to post a comment.